Table 2.
Comparisons between treatments (HR, 95% credibility interval (CrI)) in endocrine-sensitive patients, both for progression-free survival (column vs row) and overall survival (row vs column)
| Progression-free survival, HR (95% CrI) | |||||||||||
| Treatments | Sapat 20 mg+AI | Sapat 40 mg+AI | AI* | Lapatinib+AI | AS1402+AI | Anti-andro+AI | F250+AI | F500* | CDK4/6i+AI* | CDK4/6i+F500 | |
| Overall survival, HR (95% CrI) | Sapat 20 mg+AI | 0.85 (0.56–1.28) |
0.73 (0.49–1.10) |
0.69 (0.44–1.07) |
0.69 (0.32–1.48) |
0.60 (0.33–1.08) |
0.59 (0.38–0.93) |
0.58 (0.37–0.93) |
0.41 (0.27–0.62) |
0.34 (0.19–0.60) |
|
| Sapat 40 mg+AI | – | 0.86 (0.57–1.30) |
0.81 (0.52–1.27) |
0.82 (0.38–1.74) |
0.71 (0.39–1.28) |
0.69 (0.44–1.10) |
0.69 (0.43–1.10) |
0.48 (0.31–0.74) |
0.40 (0.22–0.70) |
||
| AI* | – | – | 0.94 (0.79–1.12) |
0.95 (0.51–1.80) |
0.82 (0.54–1.26) |
0.81 (0.67–0.98) |
0.80 (0.64–1.00) |
0.56 (0.49–0.63) |
0.46 (0.31–0.69) |
||
| Lapatinib+AI | – | – | – | 1.01 (0.52–1.96) |
0.87 (0.55–1.39) |
0.86 (0.67–1.12) |
0.85 (0.64–1.13) |
0.59 (0.48–0.74) |
0.49 (0.32–0.76) |
||
| AS1402+AI | – | – | – | – | 0.86 (0.40–1.85) |
0.85 (0.44–1.65) |
0.84 (0.42–1.64) |
0.59 (0.31–1.12) |
0.49 (0.23–1.02) |
||
| Anti-andro+AI | – | – | – | – | – | 0.99 (0.62–1.56) |
0.97 (0.60–1.56) |
0.68 (0.44–1.06) |
0.56 (0.31–1.00) |
||
| F250+AI | – | – | – | – | – | – | 0.98 (0.73–1.32) |
0.69 (0.55–0.86) |
0.57 (0.36–0.88) |
||
| F500* | – | – | 0.80 (0.47–1.38) |
– | – | – | – |
0.70 (0.54–0.91) |
0.58 (0.41–0.80) |
||
| CDK4/6i+AI* | – | – | 0.70 (0.48–1.02) |
– | – | – | – | 0.87 (0.59–1.29) |
0.82 (0.54–1.25) |
||
| CDK4/6i+F500 | – | – | 0.62 (0.37–1.02) |
– | – | – | – |
0.77 (0.63–0.95) |
0.88 (0.63–1.22) |
||
Treatments in the cells closer to the right-upper corner of the table are usually better than treatments in the cells closer to the upper-left corner. Cells in bold: statistically significant difference.
*±goserelin.
AI, aromatase inhibitor; anti-andro, anti-androgen agent; CDK, cyclin-dependent kinase; CDK4/6i, CDK4/6 inhibitor; F250, fulvestrant 250 mg; F500, fulvestrant 500 mg; sapat, sapatinib.